530207 BRAWN

Brawn Biotech Share Price

 

 

Start SIP in BRAWN

Start SIP

Performance

  • Low
  • ₹19
  • High
  • ₹19
  • 52 Week Low
  • ₹15
  • 52 Week High
  • ₹24
  • Open Price₹19
  • Previous Close₹19
  • Volume1
  • 50 DMA₹20.92
  • 100 DMA₹20.70
  • 200 DMA₹20.27

Investment Returns

  • Over 1 Month -10.15%
  • Over 3 Month -7.96%
  • Over 6 Month -2.12%
  • Over 1 Year -0.91%

Smart Investing Starts Here Start SIP with Brawn Biotech for Steady Growth!

Invest Now

Brawn Biotech Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -9
  • PEG Ratio
  • -0.1
  • Market Cap Cr
  • 6
  • P/B Ratio
  • 1.5
  • Average True Range
  • 0.98
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.25
  • RSI
  • 38.55
  • MFI
  • 89.59

Brawn Biotech Financials

Brawn Biotech Technicals

EMA & SMA

Current Price
₹18.51
-0.76 (-3.94%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹20.59
  • 50 Day
  • ₹20.92
  • 100 Day
  • ₹20.70
  • 200 Day
  • ₹20.27

Resistance and Support

18.51 Pivot Speed
  • R3 18.51
  • R2 18.51
  • R1 18.51
  • S1 18.51
  • S2 18.51
  • S3 18.51

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Brawn Biotech has an operating revenue of Rs. 16.79 Cr. on a trailing 12-month basis. An annual revenue de-growth of -18% needs improvement, Pre-tax margin of -13% needs improvement, ROE of -51% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. It is currently FORMING a base in its weekly chart and is trading around 20% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 67 which is a FAIR score but needs to improve its earnings, a RS Rating of 71 which is FAIR indicating the recent price performance, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 55 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Brawn Biotech Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-14 Quarterly Results
2025-08-13 Quarterly Results
2025-05-26 Audited Results
2025-02-12 Quarterly Results
2024-11-14 Quarterly Results

Brawn Biotech F&O

Brawn Biotech Shareholding Pattern

53.39%
0.35%
0%
0%
0%
30.97%
15.29%

Brawn Biotech FAQs

Brawn Biotech share price is ₹18 As on 07 February, 2026 | 08:12

The Market Cap of Brawn Biotech is ₹5.6 Cr As on 07 February, 2026 | 08:12

The P/E ratio of Brawn Biotech is -9 As on 07 February, 2026 | 08:12

The PB ratio of Brawn Biotech is 1.5 As on 07 February, 2026 | 08:12

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23